Currency, Actemra income boost Chugai's 3Q
This article was originally published in Scrip
Top product Avastin (bevacizumab) continued to drive growth at Chugai in the nine months ended 30 September, when the firm's Japanese sales of the anti-VEGF antibody rose by a solid 17% to JPY53.7bn ($550m).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.